- Current report filing (8-K)
2012年5月18日 - 7:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
May 14, 2012
BIO-BRIDGE SCIENCE, INC.
(Exact name of registrant as specified in
its charter)
000-51497
(Commission File Number)
DELAWARE
|
|
20-1802936
|
(State or other jurisdiction of incorporation or organization)
|
|
(IRS Employer Identification No.)
|
PO Box 168081, Chicago, IL, 60616
(Address of Principal Executive Offices,
Zip Code)
630-613-9687
(Registrant’s
telephone
number
, including area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.05 Costs Associated with Exit or Disposal Activities
In a board meeting held on May 14th, 2012, a majority
of the board directors of Bio-Bridge Science, Inc. voted to discontinue operations of the Company due to
lack of funds. The directors intend to recommend a vote for a liquidation of the Company to the shareholders. A
liquidation would result in the sale of the Company’s assets, payment of the Company’s creditors, and
ultimately distribution of any remaining proceeds to shareholders.
Item 5.02 Departure of Directors or Certain Officers
On May 15th, Dr. Liang Qiao resigned as CEO.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: May 17, 2012
/s/ Dr. Liang Qiao
|
|
By: Dr. Liang Qiao
|
|
Chairman of Board of Directors
|
|
Bio Bridge Science (CE) (USOTC:BGES)
過去 株価チャート
から 6 2024 まで 7 2024
Bio Bridge Science (CE) (USOTC:BGES)
過去 株価チャート
から 7 2023 まで 7 2024